OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Acute Migraine: Can the New Drugs Clinically Outpace?
Alok Singh, Dhyuti Gupta, Ajaya Kumar Sahoo
SN Comprehensive Clinical Medicine (2020) Vol. 2, Iss. 8, pp. 1132-1138
Closed Access | Times Cited: 23
Alok Singh, Dhyuti Gupta, Ajaya Kumar Sahoo
SN Comprehensive Clinical Medicine (2020) Vol. 2, Iss. 8, pp. 1132-1138
Closed Access | Times Cited: 23
Showing 23 citing articles:
Long-term treatment with lasmiditan in patients with migraine: post hoc analysis of treatment patterns and outcomes from the open-label extension of the CENTURION randomized trial
Mika Komori, Akichika Ozeki, Yuka Tanji, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 22
Mika Komori, Akichika Ozeki, Yuka Tanji, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 22
Multi-omics Mendelian randomization integrating GWAS, eQTL and pQTL data revealed GSTM4 as a potential drug target for migraine
Xinyue Sun, Bohong Chen, Yi Qi, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 9
Xinyue Sun, Bohong Chen, Yi Qi, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 9
Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study
Aubrey Manack Adams, Susan Hutchinson, Ella Engstrom, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 9
Aubrey Manack Adams, Susan Hutchinson, Ella Engstrom, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 9
What to do with non-responders to CGRP(r) monoclonal antibodies: switch to another or move to gepants?
Marta Waliszewska‐Prosół, Doğa Vurallı, Paolo Martelletti
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 9
Marta Waliszewska‐Prosół, Doğa Vurallı, Paolo Martelletti
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 9
Calcitonin gene-related peptide antagonists in pregnancy: a disproportionality analysis in VigiBase®
Roberta Noseda, Francesca Bedussi, Claudio Gobbi, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 3
Roberta Noseda, Francesca Bedussi, Claudio Gobbi, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 3
Fabrication of polyvinyl alcohol based fast dissolving oral strips of sumatriptan succinate and metoclopramide HCL
Muhammad Zaman, Rabia Hassan, Sobia Razzaq, et al.
Science Progress (2020) Vol. 103, Iss. 4
Open Access | Times Cited: 22
Muhammad Zaman, Rabia Hassan, Sobia Razzaq, et al.
Science Progress (2020) Vol. 103, Iss. 4
Open Access | Times Cited: 22
Deprescribing in migraine
Paolo Martelletti, Michelangelo Luciani, Valerio Spuntarelli, et al.
Expert Opinion on Drug Safety (2021) Vol. 20, Iss. 6, pp. 623-625
Closed Access | Times Cited: 20
Paolo Martelletti, Michelangelo Luciani, Valerio Spuntarelli, et al.
Expert Opinion on Drug Safety (2021) Vol. 20, Iss. 6, pp. 623-625
Closed Access | Times Cited: 20
Situational prevention in migraine: are we doing the right thing?
Lanfranco Pellesi, Paolo Martelletti
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 2
Lanfranco Pellesi, Paolo Martelletti
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 2
Understanding the efficacy and tolerability of migraine treatment: a deep dive into CGRP antagonists
Marta Waliszewska‐Prosół, Bianca Raffaelli, Marcin Straburzyński, et al.
Expert Review of Clinical Pharmacology (2024) Vol. 17, Iss. 11, pp. 1039-1051
Closed Access | Times Cited: 2
Marta Waliszewska‐Prosół, Bianca Raffaelli, Marcin Straburzyński, et al.
Expert Review of Clinical Pharmacology (2024) Vol. 17, Iss. 11, pp. 1039-1051
Closed Access | Times Cited: 2
Combination therapy in migraine: asset or issue?
Paolo Martelletti
Expert Review of Neurotherapeutics (2020) Vol. 20, Iss. 10, pp. 995-996
Open Access | Times Cited: 19
Paolo Martelletti
Expert Review of Neurotherapeutics (2020) Vol. 20, Iss. 10, pp. 995-996
Open Access | Times Cited: 19
Positioning the new drugs for migraine
Silvia Benemei, Enrico Bentivegna, Paolo Martelletti
Expert Opinion on Drug Metabolism & Toxicology (2022) Vol. 18, Iss. 1, pp. 1-3
Open Access | Times Cited: 12
Silvia Benemei, Enrico Bentivegna, Paolo Martelletti
Expert Opinion on Drug Metabolism & Toxicology (2022) Vol. 18, Iss. 1, pp. 1-3
Open Access | Times Cited: 12
Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II randomized trials
Richard B. Lipton, Rashmi B. Halker Singh, Dennis A. Revicki, et al.
The Journal of Headache and Pain (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 10
Richard B. Lipton, Rashmi B. Halker Singh, Dennis A. Revicki, et al.
The Journal of Headache and Pain (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 10
New drugs targeting calcitonin gene-related peptide for the management of migraines
Claudio Tana, Francesco Cipollone, Maria Adele Giamberardino, et al.
Expert Opinion on Emerging Drugs (2023) Vol. 28, Iss. 4, pp. 233-240
Closed Access | Times Cited: 4
Claudio Tana, Francesco Cipollone, Maria Adele Giamberardino, et al.
Expert Opinion on Emerging Drugs (2023) Vol. 28, Iss. 4, pp. 233-240
Closed Access | Times Cited: 4
Ubrogepant Is Safe and Efficacious in Participants Taking Concomitant Preventive Medication for Migraine: A Pooled Analysis of Phase 3 Trials
Andrew Blumenfeld, Kerry Knievel, Aubrey Manack Adams, et al.
Advances in Therapy (2021) Vol. 39, Iss. 1, pp. 692-705
Open Access | Times Cited: 9
Andrew Blumenfeld, Kerry Knievel, Aubrey Manack Adams, et al.
Advances in Therapy (2021) Vol. 39, Iss. 1, pp. 692-705
Open Access | Times Cited: 9
Atogepant for Migraine Prevention: A Systematic Review of Efficacy and Safety
Alok Singh, Mahesh Kumar Balasundaram
Clinical Drug Investigation (2022) Vol. 42, Iss. 4, pp. 301-308
Closed Access | Times Cited: 6
Alok Singh, Mahesh Kumar Balasundaram
Clinical Drug Investigation (2022) Vol. 42, Iss. 4, pp. 301-308
Closed Access | Times Cited: 6
Network Pharmacology-Based Investigation on Therapeutic Mechanisms of the Angelica dahurica Radix and Ligusticum chuanxiong Rhizoma Herb Pair for Anti-Migraine Effect
Chu Duc Thanh, Chu Van Men, Hyung Min Kim, et al.
Plants (2022) Vol. 11, Iss. 17, pp. 2196-2196
Open Access | Times Cited: 6
Chu Duc Thanh, Chu Van Men, Hyung Min Kim, et al.
Plants (2022) Vol. 11, Iss. 17, pp. 2196-2196
Open Access | Times Cited: 6
Ditans vs Gepants
Alok Singh, Dhyuti Gupta, Abhishek Singh
Neurology India (2021) Vol. 69, Iss. Suppl 1, pp. S43-S50
Closed Access | Times Cited: 8
Alok Singh, Dhyuti Gupta, Abhishek Singh
Neurology India (2021) Vol. 69, Iss. Suppl 1, pp. S43-S50
Closed Access | Times Cited: 8
Design, synthesis and biological evaluation of pyridinylmethylenepiperidine derivatives as potent 5-HT1F receptor agonists for migraine therapy
Chuanfei Jin, Chao Yi, Wenhe Zhong, et al.
European Journal of Medicinal Chemistry (2021) Vol. 225, pp. 113782-113782
Closed Access | Times Cited: 5
Chuanfei Jin, Chao Yi, Wenhe Zhong, et al.
European Journal of Medicinal Chemistry (2021) Vol. 225, pp. 113782-113782
Closed Access | Times Cited: 5
Efficacy and safety of ubrogepant for migraine: a meta-analysis of randomized controlled studies
Shuzhi Wu, Linglong Chen
International Journal of Neuroscience (2022) Vol. 134, Iss. 2, pp. 124-130
Closed Access | Times Cited: 3
Shuzhi Wu, Linglong Chen
International Journal of Neuroscience (2022) Vol. 134, Iss. 2, pp. 124-130
Closed Access | Times Cited: 3
New therapeutic options in migraine treatment
Aleksandra Kłos, Mateusz Pawlicki, Karol Stachyrak, et al.
Journal of Education Health and Sport (2024) Vol. 56, pp. 22-36
Open Access
Aleksandra Kłos, Mateusz Pawlicki, Karol Stachyrak, et al.
Journal of Education Health and Sport (2024) Vol. 56, pp. 22-36
Open Access
Trends and prescribing patterns of antimigraine medicines in nine major cities in China from 2018 to 2022: a retrospective prescription analysis
Jing Huang, Xinwei Wang, Yiyi Jin, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access
Jing Huang, Xinwei Wang, Yiyi Jin, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access
New Gepants Against Acute Migraine
Dhyuti Gupta, Suryaprakash Dhaneria, Alok Singh
Amrita Journal of Medicine (2021) Vol. 17, Iss. 4, pp. 109-115
Open Access | Times Cited: 1
Dhyuti Gupta, Suryaprakash Dhaneria, Alok Singh
Amrita Journal of Medicine (2021) Vol. 17, Iss. 4, pp. 109-115
Open Access | Times Cited: 1
Treating acute migraine with ubrogepant
Erin S. Schoenfuss
JAAPA (2023) Vol. 36, Iss. 9, pp. 25-28
Closed Access
Erin S. Schoenfuss
JAAPA (2023) Vol. 36, Iss. 9, pp. 25-28
Closed Access
